Molnupiravir: A new candidate for COVID‐19 treatment

F Pourkarim, S Pourtaghi‐Anvarian… - Pharmacology …, 2022 - Wiley Online Library
The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …

Antifungal drugs TDM: trends and update

B Kably, M Launay, A Derobertmasure… - Therapeutic Drug …, 2022 - journals.lww.com
Purpose: The increasing burden of invasive fungal infections results in growing challenges
to antifungal (AF) therapeutic drug monitoring (TDM). This review aims to provide an …

Variable effects of underlying diseases on the prognosis of patients with COVID-19

YJ Choi, JY Park, HS Lee, J Suh, JY Song, MK Byun… - PLoS …, 2021 - journals.plos.org
Underlying diseases might be risk factors for poor prognosis in patients with coronavirus
disease (COVID-19); however, we still do not know whether these diseases are independent …

Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies

M Biswas, N Sawajan, T Rungrotmongkol… - Frontiers in …, 2022 - frontiersin.org
Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19)
pandemic situations without establishing clinical effectiveness or tailoring safety. A …

[HTML][HTML] Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy in the United States: an analysis of the National Health and Nutrition …

E Igho-Osagie, K Brzozowski, H Jin, J Brown… - Clinical Therapeutics, 2023 - Elsevier
Purpose The evolving epidemiology and treatment landscape of COVID-19 necessitates
research into potential drug-drug interactions (pDDIs) from the use of new treatments for …

Drug-drug interactions among patients hospitalized with COVID-19 in Greece

M Spanakis, P Ioannou, S Tzalis, V Papakosta… - Journal of Clinical …, 2022 - mdpi.com
The modulation of the pharmacological action of drugs due to drug-drug interactions (DDIs)
is a critical issue in healthcare. The aim of this study was to evaluate the prevalence and the …

In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir

Q Zhang, PW Melchert, JS Markowitz - Chemico-Biological Interactions, 2022 - Elsevier
Abstract Remdesivir (RDV, Veklury®) is an FDA-approved prodrug for the treatment of
hospitalized patients with COVID-19. Recent in vitro studies have indicated that human …

Drug interactions for patients with respiratory diseases receiving COVID-19 emerged treatments

M Spanakis, A Patelarou, E Patelarou… - International Journal of …, 2021 - mdpi.com
Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems
worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to …

Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID‐19

P Biever, DL Staudacher, MJ Sommer… - Pharmacology …, 2021 - Wiley Online Library
Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption
device are applied in the treatment of severe COVID‐19. The CytoSorb® adsorber consists …

[HTML][HTML] Scoping insight on antiviral drugs against COVID-19

AS Ali, IM Ibrahim, AS Burzangi, RH Ghoneim… - Arabian Journal of …, 2021 - Elsevier
Background COVID-19 is an ongoing viral pandemic produced by SARS-CoV-2. In light of in
vitro efficacy, several medications were repurposed for its management. During clinical use …